Skip to content
Menu
About Us
Overview
Management Team
Board of Directors
Contact Us
Royalty Portfolio
Opportunities
Overview
Royalty Acquisition
Assets Available for Licensing
Phage Display Platform
Ebopiprant
Anti-prolactin Antibody
XMetA Portfolio
News
Company & Partner News
Press Releases
Investors
Overview
News & Events
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Governance
Contact
Menu
About Us
Overview
Management Team
Board of Directors
Contact Us
Royalty Portfolio
Opportunities
Overview
Royalty Acquisition
Assets Available for Licensing
Phage Display Platform
Ebopiprant
Anti-prolactin Antibody
XMetA Portfolio
News
Company & Partner News
Press Releases
Investors
Overview
News & Events
Financial Information
Stock Data
Analyst Coverage
SEC Filings
Governance
Contact
Clinical Trials
PBF-999
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers
Study of PBF-999 in Solid Tumour Advanced Cancer
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers